Works by Imamura, Chiyo K.
Results: 27
Clinical impact of baseline renal function on safety and early discontinuation of adjuvant capecitabine plus oxaliplatin in elderly patients with resected colon cancer: a multicenter post-marketing surveillance study.
- Published in:
- Japanese Journal of Clinical Oncology, 2020, v. 50, n. 2, p. 122, doi. 10.1093/jjco/hyz149
- By:
- Publication type:
- Article
A double‐blind, randomized, multicenter phase 3 study of palonosetron vs granisetron combined with dexamethasone and fosaprepitant to prevent chemotherapy‐induced nausea and vomiting in patients with breast cancer receiving anthracycline and cyclophosphamide
- Published in:
- Cancer Medicine, 2020, v. 9, n. 10, p. 3319, doi. 10.1002/cam4.2979
- By:
- Publication type:
- Article
A genome-wide association study identifies locus at 10q22 associated with clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients in Japanese.
- Published in:
- Human Molecular Genetics, 2012, v. 21, n. 7, p. 1665, doi. 10.1093/hmg/ddr597
- By:
- Publication type:
- Article
Application of PBPK Modeling and Virtual Clinical Study Approaches to Predict the Outcomes of CYP2D6 Genotype-Guided Dosing of Tamoxifen.
- Published in:
- CPT: Pharmacometrics & Systems Pharmacology, 2018, v. 7, n. 7, p. 474, doi. 10.1002/psp4.12307
- By:
- Publication type:
- Article
Impact of cytochrome P450 2C19 polymorphisms on the pharmacokinetics of tacrolimus when coadministered with voriconazole.
- Published in:
- Journal of Clinical Pharmacology, 2016, v. 56, n. 4, p. 408, doi. 10.1002/jcph.605
- By:
- Publication type:
- Article
A Phase II Study of Regorafenib With a Lower Starting Dose in Patients With Metastatic Colorectal Cancer: Exposure-Toxicity Analysis of Unbound Regorafenib and Its Active Metabolites (RESET Trial).
- Published in:
- 2020
- By:
- Publication type:
- journal article
Sunitinib-induced severe toxicities in a Japanese patient with the ABCG2 421 AA genotype.
- Published in:
- BMC Cancer, 2014, v. 14, n. 1, p. 1, doi. 10.1186/1471-2407-14-964
- By:
- Publication type:
- Article
Evaluation of clinical validity of an S-1 dosage formula based on renal function using data of the SPIRITS and the G-SOX trials.
- Published in:
- Gastric Cancer, 2022, v. 25, n. 4, p. 770, doi. 10.1007/s10120-022-01291-z
- By:
- Publication type:
- Article
Concentrations of Irinotecan and SN-38 in the Ascites and the Fluid Product of Cell-Free and Concentrated Ascites Reinfusion Therapy 9 Days After Administration of Irinotecan in a Patient with Gastric Cancer: A Case Report.
- Published in:
- OncoTargets & Therapy, 2024, v. 17, p. 1089, doi. 10.2147/OTT.S486272
- By:
- Publication type:
- Article
Sunitinib-induced severe toxicities in a Japanese patient with the ABCG2 421 AA genotype.
- Published in:
- 2014
- By:
- Publication type:
- journal article
Prospective evaluation of the relationship between response and exposure of total and unbound erlotinib in non-small cell lung cancer patients.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Evaluation of gefitinib systemic exposure in EGFR-mutated non-small cell lung cancer patients with gefitinib-induced severe hepatotoxicity.
- Published in:
- 2020
- By:
- Publication type:
- journal article
The effects of advanced age and serum α<sub>1</sub>-acid glycoprotein on docetaxel unbound exposure and dose-limiting toxicity in cancer patients.
- Published in:
- British Journal of Clinical Pharmacology, 2017, v. 83, n. 11, p. 2416, doi. 10.1111/bcp.13354
- By:
- Publication type:
- Article
Definitive chemoradiotherapy with paclitaxel for locally advanced esophageal squamous cell carcinoma in older patients (PARADISE-1): a phase I trial.
- Published in:
- BMC Cancer, 2024, v. 24, n. 1, p. 1, doi. 10.1186/s12885-024-12653-4
- By:
- Publication type:
- Article
Pharmacokinetics, Efficacy and Safety of Bosutinib in a Pediatric Patient With Chronic Myeloid Leukemia.
- Published in:
- Journal of Pediatric Pharmacology & Therapeutics, 2020, v. 25, n. 8, p. 742, doi. 10.5863/1551-6776-25.8.742
- By:
- Publication type:
- Article
Prospective evaluation and refinement of an S‐1 dosage formula based on renal function for clinical application.
- Published in:
- Cancer Science, 2021, v. 112, n. 2, p. 751, doi. 10.1111/cas.14758
- By:
- Publication type:
- Article
Clinical benefits of adding olanzapine to 5-HT<sub>3</sub> receptor antagonist, NK<sub>1</sub> receptor antagonist, and dexamethasone for the prevention of nausea and vomiting in highly emetogenic chemotherapy: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023 from the Japan Society of Clinical Oncology
- Published in:
- International Journal of Clinical Oncology, 2025, v. 30, n. 1, p. 27, doi. 10.1007/s10147-024-02663-4
- By:
- Publication type:
- Article
Efficacy and safety of multi-day antiemetic treatment for patients undergoing multi-day chemotherapy: a systematic review of Clinical Practice Guidelines for Antiemesis 2023 from Japan Society of Clinical Oncology.
- Published in:
- International Journal of Clinical Oncology, 2025, v. 30, n. 1, p. 17, doi. 10.1007/s10147-024-02652-7
- By:
- Publication type:
- Article
Efficacy and safety of dexamethasone sparing for the prevention of nausea and vomiting associated with moderately emetogenic chemotherapy: a systematic review and meta-analysis of Clinical Practice Guidelines for Antiemesis 2023 from Japan Society of Clinical Oncology
- Published in:
- International Journal of Clinical Oncology, 2024, v. 29, n. 12, p. 1785, doi. 10.1007/s10147-024-02643-8
- By:
- Publication type:
- Article
Defining the clinical benefits of adding a neurokinin-1 receptor antagonist to control chemotherapy-induced nausea and vomiting in moderately emetogenic chemotherapy: a systematic review and meta-analysis of the clinical practice guidelines for antiemesis 2023 from the Japan society of clinical oncology
- Published in:
- International Journal of Clinical Oncology, 2024, v. 29, n. 11, p. 1616, doi. 10.1007/s10147-024-02623-y
- By:
- Publication type:
- Article
Efficacy and safety of dexamethasone sparing for the prevention of nausea and vomiting associated with highly emetogenic risk antineoplastic agents: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023 from the Japan Society of Clinical Oncology
- Published in:
- International Journal of Clinical Oncology, 2024, v. 29, n. 11, p. 1632, doi. 10.1007/s10147-024-02624-x
- By:
- Publication type:
- Article
Non-pharmacological treatments for anticipatory nausea and vomiting during chemotherapy: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023.
- Published in:
- International Journal of Clinical Oncology, 2024, v. 29, n. 7, p. 889, doi. 10.1007/s10147-024-02536-w
- By:
- Publication type:
- Article
2023 Japan Society of clinical oncology clinical practice guidelines update for antiemesis.
- Published in:
- International Journal of Clinical Oncology, 2024, v. 29, n. 7, p. 873, doi. 10.1007/s10147-024-02535-x
- By:
- Publication type:
- Article
Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: Update summary of the 2015 Japan Society of Clinical Oncology Clinical Practice Guidelines for Antiemesis.
- Published in:
- International Journal of Clinical Oncology, 2021, v. 26, n. 1, p. 1, doi. 10.1007/s10147-020-01818-3
- By:
- Publication type:
- Article
The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV.
- Published in:
- International Journal of Clinical Oncology, 2019, v. 24, n. 7, p. 731, doi. 10.1007/s10147-019-01431-z
- By:
- Publication type:
- Article
Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy-the P-SELECT trial (WJOG10617G)-a randomised phase II trial by the West Japan Oncology Group.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Phase I study of salazosulfapyridine in combination with cisplatin and pemetrexed for advanced non-small-cell lung cancer.
- Published in:
- Cancer Science, 2017, v. 108, n. 9, p. 1843, doi. 10.1111/cas.13309
- By:
- Publication type:
- Article